Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ANG005
MIFTS: 54

Anogenital Venereal Wart

Categories: Gastrointestinal diseases, Infectious diseases, Oral diseases, Reproductive diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Anogenital Venereal Wart

About this section

MalaCards integrated aliases for Anogenital Venereal Wart:

Name: Anogenital Venereal Wart 12 15 17
Genital Warts 12 56 44 15 3
Condylomata Acuminata 45 74
Condyloma Acuminatum 12 77
Anogenital Human Papilloma Virus Infectious Disease 12
Genital Wart Virus Infectious Disease 12
Anogenital Warts 12
Venereal Wart 12

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Oral diseases Reproductive diseases Gastrointestinal diseases Skin diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:11168
ICD9CM 36 078.11
MeSH 45 D003218
NCIt 51 C2960 C4820
SNOMED-CT 69 22020001
ICD10 34 A63.0
Sources

Summaries for Anogenital Venereal Wart

About this section
MedlinePlus : 44 Genital warts are a sexually transmitted disease (STD) caused by the human papillomavirus (HPV). The warts usually appear as a small bump or group of bumps in the genital area. They are flesh-colored and can be flat or look bumpy like cauliflower. Some genital warts are so small you cannot see them. In women, the warts usually occur in or around the vagina, on the cervix, or around the anus. In men, genital warts are less common. They may have warts on the tip of the penis, around the anus, or on the scrotum, thigh, or groin. You can get genital warts during oral, vaginal, or anal sex with an infected partner. Correct usage of latex condoms greatly reduces, but does not completely eliminate, the risk of catching or spreading HPV. The most reliable way to avoid infection is to not have anal, vaginal, or oral sex. HPV vaccines may help prevent some of the HPV infections that cause genital warts. Your health care provider usually diagnoses genital warts by seeing them. The warts might disappear on their own. If not, your health care provider can treat or remove them. HPV stays in your body even after treatment, so warts can come back. Dept. of Health and Human Services Office on Women's Health

MalaCards based summary : Anogenital Venereal Wart, also known as genital warts, is related to vulva cancer and verrucous carcinoma, and has symptoms including anogenital warts, fever and pruritus. An important gene associated with Anogenital Venereal Wart is TLR7 (Toll Like Receptor 7), and among its related pathways/superpathways are Viral carcinogenesis and Influenza A. The drugs Imiquimod and Cantharidin have been mentioned in the context of this disorder. Affiliated tissues include skin, cervix and uterus.

Disease Ontology : 12 A viral infectious disease that results in infection located in skin of vagina, cervix, uterus, anus, penis, scrotum, mouth, and throat, has material basis in human papillomaviruses (types 6 and 11), which are transmitted by direct contact with the skin during oral, genital, or anal sex with an infected partner. The infection has symptom anogenital warts.

CDC : 3 HPV is a very common virus; nearly 80 million people—about one in four—are currently infected in the United States. Learn how you can protect the children in your life from this cancer-causing virus.

Wikipedia : 77 Genital warts are a sexually transmitted infection caused by certain types of human papillomavirus... more...

Sources

Related Diseases for Anogenital Venereal Wart

About this section

Diseases related to Anogenital Venereal Wart via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 131)
# Related Disease Score Top Affiliating Genes
1 vulva cancer 31.9 CDKN2A TP53
2 verrucous carcinoma 30.8 CDKN2A TP53
3 focal epithelial hyperplasia 30.3 GP6 IFNB1 TP53
4 papilloma 30.3 CDKN2A TP53 UBE3A
5 cervix carcinoma 30.3 CDKN2A TP53
6 squamous cell papilloma 30.3 CDKN2A TP53
7 anus disease 30.1 CDKN2A MID2 TLR7
8 in situ carcinoma 29.9 CDKN2A TP53
9 penile cancer 29.8 CDKN2A TP53
10 buschke lowenstein tumor 12.2
11 squamous cell carcinoma 10.4
12 mammary paget's disease 10.4
13 septicemic plague 10.3 IFNB1 TLR7
14 balanoposthitis 10.3 CDKN2A GP6
15 cervical cancer 10.3
16 plantar wart 10.3
17 anus cancer 10.3
18 bowen's disease 10.3
19 cervical carcinosarcoma 10.3 GP6 TP53
20 bladder squamous cell carcinoma 10.2 CDKN2A TP53
21 keratinizing squamous cell carcinoma 10.2 CDKN2A TP53
22 spitz nevus 10.2 CDKN2A TP53
23 bladder carcinoma in situ 10.2 CDKN2A TP53
24 vulva squamous cell carcinoma 10.2 CDKN2A TP53
25 scrotal carcinoma 10.2 CDKN2A TP53
26 thyroid lymphoma 10.2 CDKN2A TP53
27 vulvar disease 10.2 CDKN2A TP53
28 nasal cavity adenocarcinoma 10.2 CDKN2A TP53
29 oral erosive lichen 10.2 IFNA1 IFNB1
30 bartholin's gland disease 10.2 CDKN2A TP53
31 spinal cord astrocytoma 10.2 IFNB1 TP53
32 anal squamous cell carcinoma 10.2 CDKN2A TP53
33 megaesophagus 10.2 CDKN2A TP53
34 glycogen-rich clear cell breast carcinoma 10.2 CDKN2A TP53
35 gastric adenosquamous carcinoma 10.2 CDKN2A TP53
36 murray valley encephalitis 10.2 IFNA1 IFNB1
37 oral leukoplakia 10.2 CDKN2A TP53
38 meningeal melanomatosis 10.2 CDKN2A TP53
39 dedifferentiated liposarcoma 10.2 CDKN2A TP53
40 endocervical adenocarcinoma 10.2 CDKN2A TP53
41 cervix small cell carcinoma 10.2 CDKN2A TP53
42 necrotizing sialometaplasia 10.2 CDKN2A TP53
43 cerebral primitive neuroectodermal tumor 10.2 IFNB1 TP53
44 basaloid squamous cell carcinoma 10.2 CDKN2A TP53
45 tongue disease 10.2 CDKN2A TP53
46 optic nerve neoplasm 10.2 CDKN2A TP53
47 rectal disease 10.2 CDKN2A MID2 TLR7
48 juvenile pilocytic astrocytoma 10.2 CDKN2A TP53
49 tonsil cancer 10.1 CDKN2A TP53
50 pre-malignant neoplasm 10.1 CDKN2A TP53

Graphical network of the top 20 diseases related to Anogenital Venereal Wart:



Diseases related to Anogenital Venereal Wart
Sources

Symptoms & Phenotypes for Anogenital Venereal Wart

About this section

Symptoms:

12
  • • anogenital warts

UMLS symptoms related to Anogenital Venereal Wart:


fever, pruritus, pelvic pain, penile warts
Sources

Drugs & Therapeutics for Anogenital Venereal Wart

About this section

Drugs for Anogenital Venereal Wart (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 140)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99011-02-6 57469
2
Cantharidin Approved, Investigational Phase 4 56-25-7
3
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
4
Zinc Approved, Investigational Phase 4 7440-66-6 32051
5
Epicatechin Investigational Phase 4,Phase 1 490-46-0, 35323-91-2 72276
6 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Liver Extracts Phase 4,Phase 3
9 Antibodies Phase 4
10 Immunoglobulins Phase 4
11 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Antiviral Agents Phase 4,Phase 2,Phase 1,Not Applicable
13 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Tea Phase 4,Phase 3,Phase 2,Phase 1
16 Anti-Bacterial Agents Phase 4,Phase 2,Not Applicable
17 Trace Elements Phase 4
18 Nutrients Phase 4
19 Micronutrients Phase 4
20 Insulin, Globin Zinc Phase 4,Phase 3
21 Antibiotics, Antitubercular Phase 4
22 insulin Phase 4,Phase 3
23
Cyclophosphamide Approved, Investigational Phase 3 6055-19-2, 50-18-0 2907
24
Pancrelipase Approved, Investigational Phase 3 53608-75-6
25
Benzocaine Approved, Investigational Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
26
tannic acid Approved Phase 3,Not Applicable 1401-55-4
27
Petrolatum Approved, Investigational Phase 3 8009-03-8
28
Podophyllin Approved Phase 3 9000-55-9
29 Immunosuppressive Agents Phase 3,Phase 2,Not Applicable
30 Antineoplastic Agents, Alkylating Phase 3
31 Alkylating Agents Phase 3
32 Antirheumatic Agents Phase 3
33 pancreatin Phase 3
34 Dermatologic Agents Phase 3
35 Keratolytic Agents Phase 3
36 Antimitotic Agents Phase 3
37 Antineoplastic Agents, Phytogenic Phase 3
38 Podophyllotoxin Phase 3 518-28-5
39
Coal tar Approved Phase 2 8007-45-2
40
Nitric Oxide Approved Phase 2 10102-43-9 145068
41
Sodium Citrate Approved, Investigational Phase 2 68-04-2
42
Digoxin Approved Phase 2 20830-75-5 30322 2724385
43
Furosemide Approved, Vet_approved Phase 2 54-31-9 3440
44
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
45
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
46 Ranpirnase Investigational Phase 1, Phase 2 196488-72-9
47 Ammonium trichloro(dioxoethylene-O,O'-)tellurate Phase 2,Phase 1
48 Anti-Infective Agents Phase 2,Phase 1,Not Applicable
49 Radiation-Protective Agents Phase 2,Phase 1
50 Protective Agents Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 133)
# Name Status NCT ID Phase Drugs
1 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
2 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
3 Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts Completed NCT00189293 Phase 4 Imiquimod
4 Alternate Dosing Schedules Study for HPV Vaccine Completed NCT00862810 Phase 4
5 Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage Completed NCT01082302 Phase 4 Polyphenon E (Veregen) 15% ointment
6 Cantharone for the Treatment of Perenial Warts Completed NCT03625960 Phase 4 Cantharidin;Trichloroacetic Acid
7 Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines Recruiting NCT03180034 Phase 4
8 HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) Active, not recruiting NCT02087384 Phase 4 Placebo
9 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Not yet recruiting NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
10 A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts Terminated NCT01468636 Phase 4 Oral Zinc;Placebo
11 Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City Unknown status NCT02382900 Phase 3
12 Low Dose Cyclophosphamide Treats Genital Warts Completed NCT00999986 Phase 3 cyclophosphamide
13 Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00735462 Phase 3 2.5% imiquimod cream;3.75% imiquimod cream;Placebo cream
14 Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00674739 Phase 3 Imiquimod;3.75% imiquimod cream;placebo cream
15 Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts Completed NCT00449982 Phase 3 Polyphenon E Ointment 10%, Polyphenon E Ointment 15%
16 Glizigen-Viudid-External Anogenital Warts in Children and Adolescents Completed NCT01111344 Phase 3
17 An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) Completed NCT00090285 Phase 3
18 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed NCT00092521 Phase 3
19 Efficacy and Tolerability Study of V501 in Japanese Males (V501-122) Completed NCT01862874 Phase 3
20 Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED) Completed NCT00517309 Phase 3
21 A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine Completed NCT00501137 Phase 3
22 Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016) Completed NCT00092495 Phase 3
23 Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED) Completed NCT00092482 Phase 3
24 Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015) Completed NCT00092534 Phase 3
25 A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) Completed NCT01047345 Phase 3
26 Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) Completed NCT01651949 Phase 3
27 Safety and Tolerability Study of V501 in Japanese Boys (V501-200) Completed NCT02576054 Phase 3
28 Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients Completed NCT00677677 Phase 3
29 Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age Completed NCT00423046 Phase 3
30 Topical Green Tea Ointment in Treatment of Superficial Skin Cancer Completed NCT02029352 Phase 2, Phase 3 Sinecatechins 10%;Placebo
31 Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) Completed NCT03158220 Phase 3
32 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Completed NCT00543543 Phase 3
33 Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination Completed NCT00964210 Phase 3 Licensed quadrivalent HPV vaccine, Gardasil
34 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Completed NCT00090220 Phase 3
35 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Completed NCT00092547 Phase 3
36 GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) Completed NCT01245764 Phase 3
37 Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam Completed NCT03546842 Phase 3
38 Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response Recruiting NCT03296397 Phase 3
39 Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts Recruiting NCT02750202 Phase 3
40 Radiotherapy or Imiquimod in Complex Lentigo Maligna Recruiting NCT02394132 Phase 3 Imiquimod
41 Immunogenicity From 1 Dose of Bivalent HPV Vaccine in Girls to 3 Doses of Quadrivalent Vaccine in Women: the PRIMAVERA-ESCUDDO Trial Recruiting NCT03728881 Phase 3
42 Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts Active, not recruiting NCT03532776 Phase 3 Podofilox Gel 0.5%;Condylox Topical Gel 0.5%;Placebo Gel
43 Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients Active, not recruiting NCT03525210 Phase 3
44 A Trial of X4P-001 in Patients With WHIM Syndrome Active, not recruiting NCT03005327 Phase 2, Phase 3 X4P-001;Placebo
45 Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients Not yet recruiting NCT03153566 Phase 3
46 Efficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genital Warts Not yet recruiting NCT03853785 Phase 3 Topical Podophyllin
47 Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple Blind Controlled Study Not yet recruiting NCT03901690 Phase 3 Betaglucin soluble gel 0.2%;Imiquimod 5% cream
48 Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial Not yet recruiting NCT03289260 Phase 3 Imiquimod 5% cream;Placebo cream
49 Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9 Not yet recruiting NCT03848039 Phase 3 Placebo
50 Recurrent and Nonrecurrent Condyloma Treatment Terminated NCT01639638 Phase 2, Phase 3 PROAPOPTOTIC PEPTIDE CIGB 300

Search NIH Clinical Center for Anogenital Venereal Wart

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: condylomata acuminata

Sources

Genetic Tests for Anogenital Venereal Wart

About this section
Sources

Anatomical Context for Anogenital Venereal Wart

About this section

MalaCards organs/tissues related to Anogenital Venereal Wart:

42
Skin, Cervix, Uterus, Testes, Liver, Kidney, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Anogenital Venereal Wart:

20
Skin Of Vagina
Sources

Publications for Anogenital Venereal Wart

About this section

Articles related to Anogenital Venereal Wart:

(show top 50) (show all 635)
# Title Authors Year
1
Prevalence and incidence of genital warts and cervical Human Papillomavirus infections in Nigerian women. ( 30616634 )
2019
2
Genital Warts. ( 30721297 )
2019
3
Epidemiology of genital warts in the British population: implications for HPV vaccination programmes. ( 30723185 )
2019
4
Can quadrivalent human papillomavirus prophylactic vaccine be an effective alternative for the therapeutic management of genital warts? an exploratory study. ( 30785696 )
2019
5
The interaction of high and low-risk human papillomavirus genotypes increases the risk of developing genital warts: A population-based cohort study. ( 30868650 )
2019
6
Cross-sectional study estimating the psychosocial impact of genital warts and other anogenital diseases in South Korea. ( 30898815 )
2019
7
ulsed-dye laser versus intralesional Candida albicans antigen injection in treatment of genital warts. ( 30901065 )
2019
8
Genital Warts, Lymphangioma, and Treatment with Imiquimod. ( 29803364 )
2018
9
Genital Warts, Lymphangioma, and Treatment with Imiquimod. ( 29803363 )
2018
10
Measles, mumps, and rubella vaccine in genital warts: A case report of two patients. ( 30623187 )
2018
11
Human Papillomavirus Vaccine Effectiveness Against Incident Genital Warts Among Female Health-Plan Enrollees, United States. ( 28641366 )
2018
12
Detection of human papillomavirus in urine among heterosexual men in relation to location of genital warts and circumcision status. ( 28866637 )
2018
13
Dynamics of HPV viral loads reflect the treatment effect of photodynamic therapy in genital warts. ( 29155073 )
2018
14
Annual prevalence and economic burden of genital warts in Korea: Health Insurance Review and Assessment (HIRA) service data from 2007 to 2015. ( 29235433 )
2018
15
Oral isotretinoin as an adjunctive treatment for recurrent genital warts. ( 29332721 )
2018
16
Self-reported genital warts among sexually-active university students: a cross-sectional study. ( 29334908 )
2018
17
Giant genital warts. ( 29445496 )
2018
18
Genital warts treatment: Beyond imiquimod. ( 29505317 )
2018
19
Substantially reduced incidence of genital warts in women and men six years after HPV vaccine availability in Sweden. ( 29523448 )
2018
20
Sinecatechins ointment 10% (Veregen®) for genital warts: percutaneous penetration of epigallocatechin gallate concentrations in the stratum corneum collected by adhesive tape stripping method. ( 29524277 )
2018
21
Sinecatechins 10% ointment for genital warts: Case report of a beneficial reaction in an HIV-positive woman. ( 29621948 )
2018
22
Prevalence and Burden Related to Genital Warts in India. ( 29717924 )
2018
23
The efficacy and safety of other cryotherapy compounds for the treatment of genital warts: a randomized controlled trial. ( 29790804 )
2018
24
Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients. ( 30019118 )
2018
25
Cantharidin is Superior to Trichloroacetic Acid for the Treatment of Non-mucosal Genital Warts: A Pilot Randomized Controlled Trial. ( 30078935 )
2018
26
Risk of genital warts in renal transplant recipients-A registry-based, prospective cohort study. ( 30080315 )
2018
27
Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial. ( 30236042 )
2018
28
A Very Common Intimate Concern: will my genital warts ever stop recurring? ( 30346559 )
2018
29
Burden of genital warts in Peru: an observational study. ( 30396319 )
2018
30
Incidence, psychosocial burden, and economic impact of genital warts in Mexico. ( 30699267 )
2018
31
Coexistence of genital lichen sclerosus and genital warts. ( 30564837 )
2018
32
Giant vulvar verruciform xanthoma can mimic a common vulvar mass, genital warts. ( 27894614 )
2017
33
HPV-6 Molecular Variants Association With the Development of Genital Warts in Men: The HIM Study. ( 28011919 )
2017
34
Prevalence and incidence of external genital warts in a sample of Italian general female population. ( 28166736 )
2017
35
Ano-Genital Warts and HIV Status- A Clinical Study. ( 28274028 )
2017
36
Human papillomavirus vaccination and genital warts in young Indigenous Australians: national sentinel surveillance data. ( 28301790 )
2017
37
Trends in genital warts diagnoses in New Zealand five years following the quadrivalent human papillomavirus vaccine introduction. ( 28337036 )
2017
38
Decline in hospitalization for genital warts in the Veneto region after an HPV vaccination program: an observational study. ( 28381294 )
2017
39
Concordance of HPV-DNA in cervical dysplasia or genital warts in women and their monogamous long-term male partners. ( 28390162 )
2017
40
Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe. ( 28400857 )
2017
41
Condyloma-like lesions in a young woman: Not always synonym of genital warts. ( 28427733 )
2017
42
Impact of Number of Human Papillomavirus Vaccine Doses on Genital Warts Diagnoses Among a National Cohort of U.S. Adolescents. ( 28499288 )
2017
43
Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain. ( 28499554 )
2017
44
Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland. ( 28531205 )
2017
45
Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure. ( 28602548 )
2017
46
Ingenol mebutate for the management of genital warts in sensitive anatomic locations. ( 28619577 )
2017
47
A cross-sectional study estimating the burden of illness related to genital warts in South Korea. ( 28674130 )
2017
48
Functional characterization of CD4 and CD8 T cell responses among human papillomavirus infected patients with ano-genital warts. ( 28770238 )
2017
49
Risk of cancer in patients with genital warts: A nationwide, population-based cohort study in Taiwan. ( 28806741 )
2017
50
HPV-11 variability, persistence and progression to genital warts in men: the HIM study. ( 28809141 )
2017
Sources

Variations for Anogenital Venereal Wart

About this section
Sources

Expression for Anogenital Venereal Wart

About this section
Search GEO for disease gene expression data for Anogenital Venereal Wart.
Sources

Pathways for Anogenital Venereal Wart

About this section

Pathways related to Anogenital Venereal Wart according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Viral carcinogenesis 38
11.94 CDKN2A TP53 UBE3A
2
Influenza A 38
Show member pathways
 11.94 IFNA1 IFNB1 TLR7 TP53
3
SMAD Signaling Network 65
11.66 CDKN2A TP53 UBE3A
4
Factors involved in megakaryocyte development and platelet production 67
11.33 IFNA1 IFNB1 TP53
5
Transcription_P53 signaling pathway 23
11.28 CDKN2A TP53 UBE3A
6
Oncogene Induced Senescence 67
10.98 CDKN2A TP53
7
BARD1 signaling events 1
10.9 TOPBP1 TP53
8
Senescence and Autophagy in Cancer 1
10.82 CDKN2A IFNB1 TP53
9
Inhibition of Ribosome Biogenesis by p14(ARF) 65
10.66 CDKN2A TP53
10
TP53 Network 1
Show member pathways
 10.6 CDKN2A TP53
Sources

GO Terms for Anogenital Venereal Wart

About this section

Biological processes related to Anogenital Venereal Wart according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.58 IFNB1 IFNA1 GP6
2 defense response to virus GO:0051607 9.54 TLR7 IFNB1 IFNA1
3 response to exogenous dsRNA GO:0043330 9.46 IFNB1 IFNA1
4 B cell proliferation GO:0042100 9.43 IFNB1 IFNA1
5 T cell activation involved in immune response GO:0002286 9.32 IFNB1 IFNA1
6 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.26 IFNB1 IFNA1
7 natural killer cell activation involved in immune response GO:0002323 9.16 IFNB1 IFNA1
8 replicative senescence GO:0090399 8.96 CDKN2A TP53
9 antigen processing and presentation, exogenous lipid antigen via MHC class Ib GO:0048007 8.62 AP3D1 CD1E

Molecular functions related to Anogenital Venereal Wart according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 9.16 TP53 CDKN2A
2 cytokine receptor binding GO:0005126 8.96 IFNA1 IFNB1
3 type I interferon receptor binding GO:0005132 8.62 IFNA1 IFNB1
Sources

Sources for Anogenital Venereal Wart

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....